News and reflections from the world of AI

    Aiforia announces CE-IVD mark for AI-supported breast cancer diagnostics

    First-of-its kind diagnostic tool Aiforia today announced the CE-IVD Mark for the Aiforia™ Clinical AI Model for Breast Cancer: Ki67, a widely used ...
    Written by Aiforia

    Neuroscientist Joan Compte describes benefits of AI in Parkinson’s Disease image analysis

    What is PD? Parkinson’s disease (PD) is a neurological disorder characterized by the degeneration of dopamine releasing regions in the brain. The ...
    Written by Aiforia

    Aiforia Raises €12.6M in Series B Funding to Enhance Precision Diagnostics and Preclinical Analysis in Pathology

    Helsinki – June 3, 2021 - Aiforia, a software company providing AI-based solutions for clinical and preclinical image analysis in pathology, ...
    Written by Aiforia
    April 29, 2021

    Automating the detection of malaria parasites in blood smear

    Introduction Malaria is a life-threatening disease caused by Plasmodium parasites and transmitted through the bites of infected female Anopheles mosquitoes. There are five parasite species that cause malaria in humans of which P. falciparum and P. vivax pose the greatest threat, often progressing to severe illness, multi-organ failure, or death.
    Written by Aiforia
    April 28, 2021

    Interview with veterinary pathologist on AI-assisted screening of bone marrow cellularity changes

    Bone marrow cellularity is the volume ratio of hematopoiesis (the body’s manufacturing of blood cells) and fat, and decreases with age. Many compounds can alter the cellularity of bone marrow making it a vital tissue for analysis by pathologists in pharmacologic safety studies. Quantitative data is vital for statistical evaluation in risk and toxicity assessments.
    Written by Aiforia
    April 22, 2021

    Aiforia and X-ZELL partner to scale up novel AI-powered method for early cancer detection

    Singapore, Helsinki -- Aiforia, a leading software company providing artificial intelligence (AI) solutions for medical image analysis, and X-ZELL, a clinical stage med-tech company aiming to make early, affordable cancer detection accessible to everyone, have entered into a strategic partnership to integrate X-ZELL’s novel rare cell detection technology with Aiforia’s deep learning AI software.
    Written by Aiforia
    1 2 3 4 5